Back to Journals » OncoTargets and Therapy
OncoTargets and Therapy
ISSN: 1178-6930
OncoTargets and Therapy is an international, peer-reviewed journal focusing on the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer. This journal explores the evidence behind new and existing therapies to aid their informed acceptance by clinicians and treatment adherence by patients.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Articles:
- View all (6490)
- Volume 17, 2024 (52)
- Volume 16, 2023 (147)
- Volume 15, 2022 (191)
- Volume 14, 2021 (525)
- Volume 13, 2020 (1171)
- Volume 12, 2019 (1075)
- Volume 11, 2018 (882)
- Volume 10, 2017 (615)
- Volume 9, 2016 (802)
- Volume 8, 2015 (439)
- Volume 7, 2014 (253)
- Volume 6, 2013 (208)
- Volume 5, 2012 (54)
- Volume 4, 2011 (19)
- Volume 3, 2010 (22)
- Volume 2, 2009 (25)
- Volume 1, 2008 (10)
Latest articles:
- 5 records -
Investigating the Cell Origin and Liver Metastasis Factors of Colorectal Cancer by Single-Cell Transcriptome Analysis
Sha Z, Gao Q, Wang L, An N, Wu Y, Wei D, Wang T, Liu C, Shen Y
OncoTargets and Therapy 2024, 17:345-358
Published Date: 17 April 2024
A Case Study of Gastric Adenocarcinoma and Squamous Cell Carcinoma of the Cervix
Liu S, Li F, Cao Q, Li N, Gao Q
OncoTargets and Therapy 2024, 17:339-344
Published Date: 15 April 2024
Primary Epithelioid Angiosarcoma of the Jejunal Mesentery Causing Abdominal Bleeding: Case Report and Literature Review
Yang P, Wu Q, Zhou Y, Li Y
OncoTargets and Therapy 2024, 17:327-338
Published Date: 10 April 2024
Traditional Chinese Medicine in Regulating Tumor Microenvironment
Wang Z, Li M, Bi L, Hu X, Wang Y
OncoTargets and Therapy 2024, 17:313-325
Published Date: 10 April 2024
MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation and BRAF V600E
Tan X, Wu Z, Chen M
OncoTargets and Therapy 2024, 17:307-312
Published Date: 9 April 2024